- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04001556
RElevance of UltraSonography for Assessing Salivary Gland Involvement in Systemic Sclerosis (SSc) (REUSSI-SSc)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Brest, France, 29000
- CHU Brest Service de Rhumatologie
-
Rennes, France, 35000
- Chu Rennes
-
Tours, France, 37000
- CHU Tours, Service de médecine interne
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients over eighteen years old;
- Fulfilling 2013 ACR classification criteria for Systemic sclerosis (Van den Hoogen et al. 2013);
- 60 patients with subjective sicca symptoms reported by a standardised questionnaire (Vitali C et al. 2002);
- 15 patients without sicca symptoms;
- Who has signed an informed consent
- Benefiting from a social security scheme
Exclusion Criteria:
- Treatment: current (or in the past 6 months) immunosuppressive treatment by rituximab or cyclophosphamide (representing less than 5% of SSc patients in the investigator's centres);
- Current (or in the past 6 months) treatment with drugs with anti-cholinergic properties (Selective Serotonin Reuptake Inhibitors and anti-histaminic inhibitors (hydroxyzine));
- Current treatment with antiplatelet aggregates
- Anti-vitamin K treatment (increasing risk of bleeding during minor salivary gland biopsy); and oral anti-coagulant
- Known abnormal coagulation (prolonged aPPT(activated partial thromboplastin time) and / or PT (Prothrombin time ( <70%)), or known thrombocytopenia (<150,000 platelets / mm3)
- Known secondary sicca symptoms : history of head-and-neck radiotherapy, hepatitis C infection, AIDS, sarcoidosis, amyloidosis, graft-vs-host disease and IgG4(Isotype's immunoGlobulin G4)-related disease;
- Pregnancy or breastfeeding mothers;
- Known intolerance/allergy to xylocain injection;
- Adults legally protected (under judicial protection, guardianship, or supervision), inability to consent.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Patients reporting subjective sicca symptoms
HAQ(Health Assessment Questionnaire) Score, bilateral schirmer 's test, unstimulated whole salivary flow rate, blood sample for immunologic evaluation
|
Minor salivary gland biopsy with injection of lidocain
Acoustic Radiation Force Impulse on Major Salivary Glands
Ultrasonography of Major Salivary Glands
|
Experimental: Patients without subjective sicca symptoms
HAQ(Health Assessment Questionnaire) score, bilateral schirmer 's test, unstimulated whole salivary flow rate, blood sample for immunologic evaluation
|
Acoustic Radiation Force Impulse on Major Salivary Glands
Ultrasonography of Major Salivary Glands
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Ultrasonography characteristics of major salivary glands
Time Frame: up to six months (at evaluation visit)
|
Ultrasonography characteristics of major salivary glands based on Salaffi's composite score. each MSG will be scored as followed:
In each patient, 4 grades can be obtained (1 grade per gland); the sum of these 4 grades (range 0-16) will be the Salaffi's score. A score of 0 has the best outcome, of 16 the worse |
up to six months (at evaluation visit)
|
Ultrasonography characteristics of major salivary glands
Time Frame: up to six months (at evaluation visit)
|
Ultrasonography characteristics of major salivary glands based on bilateral ARFI(Acoustic radiation force Impulse) elastometry
|
up to six months (at evaluation visit)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Variants of the Salaffi score
Time Frame: up to six months (evaluation visit)
|
Scores of Hocevar,based on the same ultrasound parameters but with a weighting different from that of Salaffi in the calculation of the score. Echostructure of the four salivary glands will be graded 0 to 12 ; the sum of these 4 grades (range 0-48) will be the Hocevar's score. A score of 0 has the best outcome, of 48 the worse. |
up to six months (evaluation visit)
|
Variants of the Salaffi score
Time Frame: up to six months (evaluation visit)
|
Scores of Milic,based on the same ultrasound parameters but with a weighting different from that of Salaffi in the calculation of the score. Echostructure of the four salivary glands will be graded 0 to 3 ; the sum of these 4 grades (range 0-12) will be the Milic's score. A score of 0 has the best outcome, of 12 the worse. |
up to six months (evaluation visit)
|
Variants of the Salaffi score
Time Frame: up to six months (evaluation visit)
|
Scores Jousse-Joulin / Cornec constituting , based on the same ultrasound parameters but with a weighting different from that of Salaffi in the calculation of the score. Echostructure of the four salivary glands will be graded 0 to 4 ; the sum of these 4 grades (range 0-16) will be the Jousse-Joulin/Cornec's score. A score of 0 has the best outcome, of 16 the worse. |
up to six months (evaluation visit)
|
Biopsy of the minor salivary glands
Time Frame: up to six months (evaluation visit)
|
Biopsies of the minor salivary glands with standardized histological characterization of the Chisholm score. Chisholm'score will evaluate the number of lymphocytic foci/4mm2 grade 1 : none or slight, grade 2 : less than 50 lymphocytes and histocytes, grade 3 : one focus with at least 50 lymphocytes, grade 4 : More than one focus with at least 50 lymphocytes, Grade 1 has the best outcome, grade 4 the worse. |
up to six months (evaluation visit)
|
Biopsy of the minor salivary glands
Time Frame: up to six months (evaluation visit)
|
Biopsies of the minor salivary glands with standardized characterization of the focus score. Focus score : the number of mononuclear cell infiltrates containing at least 50 inflammatory cells in a 4 mm2 glandular section, Focus score 0 = no mononuclear cell infiltrate containing at least 50 inflammatory cells in a 4 mm2 glandular section, Focus score =1 or >1 : one or more mononuclear cell infiltrates containing at least 50 inflammatory cells in a 4 mm2 glandular section, Focus score 0 has the best outcome Focus score =1 or >1 has the worse outcome |
up to six months (evaluation visit)
|
Biopsy of the minor salivary glands
Time Frame: up to six months (evaluation visit)
|
Biopsies of the minor salivary glands with evaluation of fibrosis assessed from F1 to F4
|
up to six months (evaluation visit)
|
Evaluation of the presence or absence of objective criteria of Sjogren
Time Frame: up to six months (evaluation visit)
|
Evaluation of the presence or absence of objective criteria of Sjogren according to salivary flow test
|
up to six months (evaluation visit)
|
Evaluation of the presence or absence of objective criteria of Sjogren
Time Frame: up to six months (evaluation visit)
|
Evaluation of the presence or absence of objective criteria of Sjogren according to Schirmer test.
|
up to six months (evaluation visit)
|
Clinical evaluation of systemic scleroderma lesions
Time Frame: up to six months (evaluation visit)
|
forms of the disease
|
up to six months (evaluation visit)
|
Clinical evaluation of systemic scleroderma lesions
Time Frame: up to six months (evaluation visit)
|
duration of evolution of the disease
|
up to six months (evaluation visit)
|
Clinical evaluation of systemic scleroderma lesions
Time Frame: up to six months (evaluation visit)
|
visceral damage : Presence or absence of pulmonary involvement on CT scan, Presence or absence of pulmonary arterial hypertension on echocardiography.
|
up to six months (evaluation visit)
|
Clinical evaluation of systemic scleroderma lesions
Time Frame: up to six months (evaluation visit)
|
immunological data : Positivity of : Anti SSA(Anti Sjögren Syndrom A) antibodies,Anti SSb(Anti Sjögren syndrom B) antibodies,Anti Topoisomerase antibodies, Anti Centromere antibodies, Anti RNA polymerase III antibodies Using Indirect ImmunoFluorescence (IFI) ( as binary parameter (positive or negative) |
up to six months (evaluation visit)
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Patrick JEGO, MD, University Hospital of Rennes
Publications and helpful links
General Publications
- Salaffi F, Argalia G, Carotti M, Giannini FB, Palombi C. Salivary gland ultrasonography in the evaluation of primary Sjogren's syndrome. Comparison with minor salivary gland biopsy. J Rheumatol. 2000 May;27(5):1229-36.
- Hocevar A, Ambrozic A, Rozman B, Kveder T, Tomsic M. Ultrasonographic changes of major salivary glands in primary Sjogren's syndrome. Diagnostic value of a novel scoring system. Rheumatology (Oxford). 2005 Jun;44(6):768-72. doi: 10.1093/rheumatology/keh588. Epub 2005 Mar 1.
- Milic VD, Petrovic RR, Boricic IV, Radunovic GL, Pejnovic NN, Soldatovic I, Damjanov NS. Major salivary gland sonography in Sjogren's syndrome: diagnostic value of a novel ultrasonography score (0-12) for parenchymal inhomogeneity. Scand J Rheumatol. 2010 Mar;39(2):160-6. doi: 10.3109/03009740903270623.
- Jousse-Joulin S, Milic V, Jonsson MV, Plagou A, Theander E, Luciano N, Rachele P, Baldini C, Bootsma H, Vissink A, Hocevar A, De Vita S, Tzioufas AG, Alavi Z, Bowman SJ, Devauchelle-Pensec V; US-pSS Study Group. Is salivary gland ultrasonography a useful tool in Sjogren's syndrome? A systematic review. Rheumatology (Oxford). 2016 May;55(5):789-800. doi: 10.1093/rheumatology/kev385. Epub 2015 Dec 14.
- Cornec D, Jousse-Joulin S, Pers JO, Marhadour T, Cochener B, Boisrame-Gastrin S, Nowak E, Youinou P, Saraux A, Devauchelle-Pensec V. Contribution of salivary gland ultrasonography to the diagnosis of Sjogren's syndrome: toward new diagnostic criteria? Arthritis Rheum. 2013 Jan;65(1):216-25. doi: 10.1002/art.37698.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 35RC18_9905
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Systemic Sclerosis
-
Horizon Pharma Ireland, Ltd., Dublin IrelandEnrolling by invitationDiffuse Cutaneous Systemic Sclerosis | Sclerosis, SystemicKorea, Republic of, France, United States, Spain, Mexico, Japan, Argentina, Greece, Israel
-
W. Leroy GriffingRecruitingSystemic Sclerosis | Scleroderma, Systemic | Scleroderma, Diffuse | Diffuse Cutaneous Systemic Sclerosis | Interstitial Lung Disease | Scleroderma | Systemic Sclerosis, Diffuse | Diffuse Systemic Sclerosis | Pulmonary Fibrosis Interstitial | Diffuse Scleroderma | Diffuse Cutaneous Scleroderma | Progressive Systemic... and other conditionsUnited States
-
Horizon Therapeutics Ireland DACRecruitingDiffuse Cutaneous Systemic Sclerosis | Sclerosis, SystemicNetherlands, Spain, Germany, United States, Japan, France, Italy, Korea, Republic of, Portugal, Israel, Greece, Argentina, Austria, Mexico, Poland, Switzerland, United Kingdom, Romania, Chile
-
Fred Hutchinson Cancer CenterNational Institute of Allergy and Infectious Diseases (NIAID)CompletedSystemic Scleroderma | Severe Systemic SclerosisUnited States
-
University of ManchesterCompletedEarly Diffuse Cutaneous Systemic Sclerosis
-
Kadmon, a Sanofi CompanyTerminatedDiffuse Cutaneous Systemic Sclerosis | System; SclerosisUnited States
-
Boston UniversityCompleted
-
Federal University of São PauloUnknown
-
Lawson Health Research InstituteMallinckrodtNot yet recruitingDiffuse Cutaneous Systemic SclerosisCanada
-
Mitsubishi Tanabe Pharma America Inc.CompletedDiffuse Cutaneous Systemic SclerosisSpain, Belgium, United States, United Kingdom, Poland, Canada, Germany, Italy
Clinical Trials on Minor Salivary gland Biopsy
-
National Taiwan University HospitalUnknownChronic Graft Versus Host Disease | Sjogren Syndrome | Mucous Membrane Pemphigoid | Cicatrizing Conjunctivitis | Stevens-Johnson Syndrome Toxic Epidermal Necrolysis Spectrum | Chemical Burn to EyeTaiwan
-
Unity Health TorontoPfizerNot yet recruiting
-
University Hospital, BordeauxRecruitingSjogren's SyndromeFrance
-
National Council of Scientific and Technical Research...UnknownLymphoma, Non-Hodgkin | Primary Sjögren Syndrome
-
AHS Cancer Control AlbertaCross Cancer InstituteUnknown
-
University of PisaRecruiting
-
Federal University of São PauloCompletedDry Eye | Transplantation | Ocular Surface Disease | SymblepharonBrazil
-
Radiation Therapy Oncology GroupNational Cancer Institute (NCI)CompletedHead and Neck Cancer | Xerostomia | Radiation ToxicityUnited States, Canada
-
The Christie NHS Foundation TrustSuspended
-
Mayo ClinicCompletedParkinson DiseaseUnited States